Related Experiment Video
Updated: Aug 6, 2026

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
Bioavailability of sodium valproate suppositories during repeated administration at steady state in epileptic
1Swiss Epilepsy Center Zürich, Switzerland.
Insights
Rectal sodium valproate (NaVPA) suppositories offer comparable bioavailability to oral forms for epilepsy patients. Repeated use showed good tolerability without significant local irritation or increased stool frequency.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Epileptology
Background:
- Oral antiepileptic drug administration is not always feasible.
- Rectal sodium valproate (NaVPA) is a potential alternative route.
- Limited data exists on repeated NaVPA suppository use.
Purpose of the Study:
- To assess the bioavailability of rectal NaVPA suppositories.
- To evaluate local effects of repeated NaVPA suppository administration.
- To compare serum VPA levels between oral and rectal routes.
Main Methods:
- 13 epileptic children and adolescents on chronic NaVPA therapy were studied.
- Serum VPA levels were measured under steady-state conditions before and after suppository use.
- Bioavailability was calculated using AUC (Area Under the Curve) over 24 hours.
Main Results:
- Average NaVPA bioavailability was 112.4% for oral solution and 99.5% for enteric-coated tablets.
- Serum VPA level fluctuations were similar for suppositories and oral solution.
- No significant local irritation or increased stool frequency was observed.
Conclusions:
- NaVPA suppositories demonstrate comparable bioavailability to oral forms.
- Rectal NaVPA is well-tolerated for repeated administration.
- Suppositories provide a viable alternative when oral administration is not possible.
Abstract:
Oral administration of antiepileptic drugs can temporarily be impossible under certain conditions, such as altered states of consciousness, spike-wave stupour, gastro-intestinal disturbances with nausea and vomiting, prior to or during surgery or certain diagnostic procedures, and because of drug refusal in patients with mental retardation or psychiatric problems. Although rectal administration of sodium valproate (NaVPA) has been shown to be a possible alternative route, little is known about the bioavailability and local effects during repeated administration of NaVPA suppositories. These aspects were investigated in 13 epileptic children and adolescents on chronic NaVPA therapy. Eight patients were treated with the oral solution (Group A; mean age 10.6 years) and five patients with enteric coated tablets (Group B, mean age 16.4 years). In every patient five serum levels of VPA over a 24 h period were measured under steady-state conditions. Thereafter, suppositories were administered for 2-7 days and serum levels were again determined (identical dosing and sampling times). Bioavailability of NaVPA was calculated on the basis of the area under the concentration vs. time curve over 24 h. The average bioavailability for suppositories compared with the oral form was 112.4% in Group A and 99.5% in Group B. Fluctuations of serum VPA levels were very similar with suppositories and oral solution, and more pronounced than with the enteric coated tablets. Stool frequency was not increased by repeated administration of suppositories, except for a three-fold increase in one patient. There was no objective or subjective evidence of local irritation from the suppositories. In conclusion, NaVPA suppositories have the same bioavailability under steady-state conditions as oral preparations and they are well tolerated.(ABSTRACT TRUNCATED AT 250 WORDS)
Related Concept Videos
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Dosage Regimen: Multiple Oral Dosage
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Excretion

